Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.

Christoph S, Lee-Sherick AB, Sather S, DeRyckere D, Graham DK.

J Vis Exp. 2013 Sep 18;(79):e50720. doi: 10.3791/50720.

2.

UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS 3rd, Graham DK.

Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.

3.

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.

Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK.

Blood Cancer J. 2013 Jan 25;3:e101. doi: 10.1038/bcj.2012.46.

4.

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.

Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, DeRyckere D, Graham DK.

J Hematol Oncol. 2013 Jan 23;6:10. doi: 10.1186/1756-8722-6-10.

Supplemental Content

Loading ...
Support Center